NCT05907044View on ClinicalTrials.gov

A Study to Investigate the Safety, Immunogenicity of Bivalent mRNA Vaccine RQ3027 and RQ3025 as a Booster Dose in Healthy Adults

NACompletedINTERVENTIONAL

Enrollment

376

Participants

Timeline

Start Date

May 8, 2023

Primary Completion Date

June 10, 2023

Study Completion Date

November 23, 2023

Conditions

COVID-19

Interventions

BIOLOGICAL

RQ3013

0.15mL/dose containing mRNA 30μg

BIOLOGICAL

RQ3025

0.15mL/dose containing mRNA 30μg

BIOLOGICAL

RQ3027

0.15mL/dose containing mRNA 30μg

Trial Locations (1)

650091

The Affiliated Hospital of Yunnan University, Kunming

All Listed Sponsors

collaborator

Yunnan University

UNKNOWN

collaborator

Kunming Medical University

OTHER

lead

Affiliated Hospital of Yunnan University

OTHER

NCT05907044 - A Study to Investigate the Safety, Immunogenicity of Bivalent mRNA Vaccine RQ3027 and RQ3025 as a Booster Dose in Healthy Adults | Biotech Hunter | Biotech Hunter